US FDA approves Merus' therapy to treat lung, pancreatic cancers (updated)

Merus NV

04/12/2024 20:51

(Adds details in paragraphs 2 and 3)
       Dec 4 (Reuters) - The U.S. Food and Drug Administration
has approved Merus NV's  2GH.F  therapy that targets a
particular gene, expanding treatment options for patients with
hard-to-treat type of lung and pancreatic cancers, the health
regulator said on Wednesday.
    The therapy, branded as Bizengri, targets the NRG1 gene,
which is associated with formation and progression of several
tumors. 
    It is the first approved therapy for patients with the type
of non-small cell lung cancer and pancreatic adenocarcinoma
harboring an NRG1 gene fusion.

 (Reporting by Sriparna Roy in Bengaluru; Editing by Krishna
Chandra Eluri)
 ((Sriparna.Roy@thomsonreuters.com;))